Howe & Rusling’s Lifecore Biomedical LFCR Stock Holding History

Howe & Rusling’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-375	Closed	-$5K	–	887
2018 Q1	$5K	Buy	375 +100	+36%	+$1.31K	﹤0.01%	614
2017 Q4	$3K	Hold	275	–	–	﹤0.01%	637
2017 Q3	$4K	Hold	275	–	–	﹤0.01%	618
2017 Q2	$4K	Hold	275	–	–	﹤0.01%	677
2017 Q1	$3K	Sell	275 -30	-10%	-$380	﹤0.01%	759
2016 Q4	$4K	Hold	305	–	–	﹤0.01%	723
2016 Q3	$4K	Hold	305	–	–	﹤0.01%	720
2016 Q2	$3K	Hold	305	–	–	﹤0.01%	747
2016 Q1	$3K	Buy	305 +50	+20%	+$549	﹤0.01%	782
2015 Q4	$3K	Hold	255	–	–	﹤0.01%	742
2015 Q3	$3K	Hold	255	–	–	﹤0.01%	746
2015 Q2	$4K	Hold	255	–	–	﹤0.01%	709
2015 Q1	$4K	Hold	255	–	–	﹤0.01%	658
2014 Q4	$4K	Hold	255	–	–	﹤0.01%	660
2014 Q3	$3K	Buy	+255	New	+$3.18K	﹤0.01%	701

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Howe & Rusling's LFCR Position: Q2 2018 in Review

Howe & Rusling sold out of Lifecore Biomedical (LFCR) in Q2 2018, closing a stake of 375 shares — an estimated $5K sold.

Howe & Rusling first reported a position in LFCR in Q3 2014 and held it in 15 quarters. The position peaked at $5K in Q1 2018. 92 funds tracked by Wall St. Rank hold LFCR as of Q2 2018.

Howe & Rusling reported no remaining Lifecore Biomedical position as of Q2 2018 after selling out during the quarter.
Howe & Rusling sold 375 Lifecore Biomedical shares in Q2 2018, an estimated $5K.
Howe & Rusling first reported a position in Lifecore Biomedical in Q3 2014 and held it in 15 quarters.
Howe & Rusling's Lifecore Biomedical position peaked at $5K in Q1 2018.
92 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2018.

Based on Howe & Rusling's 13F filing for Q2 2018, filed 31 Jul 2018.